Cargando…

Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer

The aim of this phase II study was to assess the feasibility and efficacy of a specific three-dimensional conformal radiotherapy technique with concurrent continuous infusion of 5-fluorouracil (CI 5FU) sandwiched between gemcitabine chemotherapy in patients with locally advanced pancreatic cancer. P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldstein, D, Van Hazel, G, Walpole, E, Underhill, C, Kotasek, D, Michael, M, Shapiro, J, Davies, T, Reece, W, Harvey, J, Spry, N
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360339/ https://www.ncbi.nlm.nih.gov/pubmed/17653074 http://dx.doi.org/10.1038/sj.bjc.6603900

Ejemplares similares

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer
por: Goldstein, D, et al.
Publicado: (2012)

Definitive Radiochemotherapy in Esophageal Cancer - A Single Institution Experience
por: Anderluh, Franc, et al.
Publicado: (2019)

Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study
por: Gagel, Bernd, et al.
Publicado: (2007)

Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma
por: Peuker, Leonie, et al.
Publicado: (2022)

Radiochemotherapy
Publicado: (1998)

Adjuvant Radiochemotherapy versus Chemotherapy Alone for Gastric Cancer: Implications for Target Definition
por: Xu, Jing, et al.
Publicado: (2019)

Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits?
por: Schiffner, Christoph, et al.
Publicado: (2022)

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
por: Ueno, Makoto, et al.
Publicado: (2020)

Assessment of Salvage Surgery in Persistent Cervical Cancer after Definitive Radiochemotherapy: A Systematic Review
por: Conte, Carmine, et al.
Publicado: (2023)

Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity
por: Paireder, Matthias, et al.
Publicado: (2020)

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
por: Wagner, A D, et al.
Publicado: (2009)

Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma
por: Lewitzki, Victor, et al.
Publicado: (2019)

Neck control after definitive radiochemotherapy without planned neck dissection in node-positive head and neck cancers
por: Jang, Na Young, et al.
Publicado: (2012)

Definitive Radiochemotherapie von lokal fortgeschrittenen Kopf-Hals-Tumoren in Kombination mit Immuncheckpointinhibition – neue Konzepte gefragt
por: Hecht, Markus, et al.
Publicado: (2021)

Combined Radiochemotherapy: Metalloproteinases Revisited
por: Waller, Verena, et al.
Publicado: (2021)

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
por: Pelzer, Uwe, et al.
Publicado: (2017)

Stevens-Johnson Syndrome Patient Received Combination Chemotherapy Gemcitabine, Cisplatin, and 5-FU for Biliary Tract Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2016)

Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner
por: Spek, C. Arnold, et al.
Publicado: (2022)

Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study
por: Pittman, K B, et al.
Publicado: (2006)

Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer
por: Wu, San-Gang, et al.
Publicado: (2017)

Definitive Radiotherapie versus Radiochemotherapie mit wöchentlich Docetaxel bei Patienten mit Kopf-Hals-Tumoren und Cisplatinunverträglichkeit
por: Schmalz, Claudia, et al.
Publicado: (2023)

Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells
por: Cho, Jae Hee, et al.
Publicado: (2017)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Concurrent radiochemotherapy in advanced hypopharyngeal cancer
por: Krstevska, Valentina, et al.
Publicado: (2010)

Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma
por: Oblak, Irena, et al.
Publicado: (2014)

Ösophaguskarzinom: Prognoseverbesserung durch neoadjuvante Radiochemotherapie
por: Knippen, Stefan, et al.
Publicado: (2021)

Infrared safe definition of jet flavour
por: Banfi, Andrea, et al.
Publicado: (2006)

Volumetric Modulated Arc Therapy Improves Outcomes in Definitive Radiochemotherapy for Anal Cancer Whilst Reducing Acute Toxicities and Increasing Treatment Compliance
por: Possiel, Jacqueline, et al.
Publicado: (2021)

Impact of EBUS-TBNA in addition to [(18)F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
por: Guberina, Maja, et al.
Publicado: (2021)

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer
por: Kunos, Charles A., et al.
Publicado: (2018)

Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin
por: Kornek, G V, et al.
Publicado: (2000)

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)
por: Di Costanzo, F, et al.
Publicado: (2005)

Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma
por: Trojan, Jörg, et al.
Publicado: (2022)

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
por: Correale, P, et al.
Publicado: (2004)

Neoadjuvante Radiochemotherapie kombiniert mit regionaler Tiefenhyperthermie beim Rektumkarzinom?
por: Ott, Oliver J.
Publicado: (2021)

Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer
por: Steber, Cole, et al.
Publicado: (2021)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
por: Kotasek, Dusan, et al.
Publicado: (2011)

Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy
por: Sturdza, Alina, et al.
Publicado: (2017)

Sigmoid volvulus: definitive surgery is safe and should be considered in all instances
por: Hardy, Niall P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rmlp9ttoa1gr306krl79ph6e84